Textbook of Autism Spectrum Disorders

Eric Hollander, M.D., is the Director of the Autism and Obsessive Compulsive Spectrum Program at the Psychiatric Research Institute of Montefiore Einstein and Professor of Psychiatry and Behavioral Sciences at Albert Einstein College of Medicine, in Bronx, New York. Randi Hagerman, M.D., is the Endowed Chair in Fragile X Research for the Medical Investigation of Neurodevelopmental Disorders (MIND) Institute and Distinguished Professor of Pediatrics in the Department of Pediatrics at the University of California, Davis Medical Center in Sacramento, California. Casara Ferretti, M.S., M.A., is a Predoctoral Research Associate in the Autism and Obsessive Compulsive Spectrum Program at the Psychiatric Research Institute of Montefiore Einstein and Professor of Psychiatry and Behavioral Sciences at Albert Einstein College of Medicine, in Bronx, New York. She is a PhD candidate in the Clinical Psychology PhD program with Health Emphasis at Ferkauf Graduate School of Psychology, Yeshiva University.

Foreword

PART I: Assessment, Evaluation, and Target Symptoms


PART IA: Assessment and Evaluation

Chapter 1. Epidemiology
Chapter 2. Psychiatric Assessment and Treatment
Chapter 3. Pediatric and Neurological Assessments
Chapter 4. Gender Dysphoria, Gender Incongruence, and Sexual Identity
Chapter 5. Racial and Ethnic Disparities in Assessment and Evaluation
Chapter 6. Digital Biomarkers in Diagnostics and Monitoring

PART IB: Target and Comorbid Symptoms

Chapter 7. Social Communication
Chapter 8. Diet and Nutrition

PART II: Causes


PART IIA: Overview

Chapter 9. Genetics and Genomics
Chapter 10. Epigenomics
Chapter 11. Prenatal, Perinatal, and Parental Risk Factors
Chapter 12. Animal Models
Chapter 13. Electrophysiological Studies
Chapter 14. Environmental Toxicity and Immune Dysregulation

PART IIB: Syndromic Causes

Chapter 15. Overview of Syndromic Causes of Autism and Commonalities in Neurobiological Pathways
Chapter 16. Fragile X Syndrome and Associated Disorders
Chapter 17. Tuberous Sclerosis Complex
Chapter 18. 16p11.2 and Other Recurrent Copy Number Variants Associated With ASD Susceptibility
Chapter 19. Rett Syndrome
Chapter 20. Prader-Willi Syndrome

PART IIC: Imaging and Anatomy

Chapter 21. Neuroanatomical Findings
Chapter 22. The Amygdala in ASD
Chapter 23. Neurobiology of ASD Informed by Structural Imaging Research
Chapter 24. Positron Emission Tomography
Chapter 25. Functional Magnetic Resonance Imaging

PART III: Treatments and Interventions


PART IIIA: Standard Pharmacological Treatments

Chapter 26. Serotonergic Medication
Chapter 27. Antipsychotics
Chapter 28. Treating Hyperactivity in Children With Pervasive Developmental Disorders

PART IIIB: Experimental Therapeutics

Chapter 29. Complementary and Integrative Approaches
Chapter 30. Oxytocin
Chapter 31. Vasopressin
Chapter 32. N-Acetylcysteine
Chapter 33. Arbaclofen: From Animal Models to Clinical Trials
Chapter 34. Cannabis, Cannabinoids, and Immunomodulatory Agents

PART IIIC: Behavioral and Educational Interventions

Chapter 35. Behavioral Treatments
Chapter 36. Early Start Denver Model
Chapter 37. The Developmental, Individual Difference, Relationship-Based Intervention Model: A Comprehensive Parent-Mediated Approach
Chapter 38. School-Based Interventions
Chapter 39. Language and Communication: Challenges and Treatments

PART IIID: Future Treatment Developments

Chapter 40. Transcranial Magnetic Stimulation
Chapter 41. Stem Cell and Gene Therapy
Chapter 42. Gene Therapy and Molecular Interventions

PART IV: Consortiums, Employment, and Advocacy

Chapter 44. Consortiums:
Developing Precision Medicine Approaches to ASD Conditions
Autism Biomarkers Consortium for Clinical Trials
Interactive Autism Network
Chapter 45. Autism Strengths and Neurodiversity
Chapter 46. Role of Patient Advocacy Groups in Treatment Development
Index